Publications: Clinical Trials and Biopharma Services

Posters:

• San Antonio Breast Cancer Symposium 2025: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer

• ESMO 2025: Long Term Survival with Leronlimab Treatment in Patients with MetastaticTriple-Negative Breast Cancer (mTNBC)

• SABCS 2024: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for Clinical Outcomes in a Phase 1/2 Clinical Trial Using SV-BR-1-GM Vaccine with the Check Point Inhibitor Retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis

• SABCS 2023: Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer

• AACR 2022:  Changes in Circulating Tumor Associated Cells Predicts Progression Free and Overall Survival in Metastatic TNBC Patients after Induction with the Anti-CCR5 Drug Leronlimab

• SABCS 2022: Decreases in Circulating Tumor Associated Cells Predict PFS and OS in a Pooled Analysis of Phase I Clinical Trials Using SV-BR-1-GM Therapy with or without Immune Check-Point Inhibitors in Metastatic Breast Cancer Patient

• Keystone Symposium Conference: SV-BR-1-GM, a breast cancer cell line with features of dendritic cells, induces tumor regression in HLA matched Stage IV breast cancer patients

Journals:

• Clin Cancer Res 2025: Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

• Clin Cancer Res (2024): Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation

• Journal of Cancer 2024: Circulating cancer-associated macrophage-like cells and macrophage-related cytokines in obese patients with advanced breast cancer who undergo neoadjuvant chemotherapy

• Scientific Reports, 2023: Cancer associated macrophage‑like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time

• ASCO (2022): Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy